Christian K Schneider
Overview
Explore the profile of Christian K Schneider including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1138
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
von Fritschen M, Janosz E, Blume C, Jagle U, Keating K, Schneider C
Mol Ther Methods Clin Dev
. 2024 Nov;
32(4):101348.
PMID: 39502574
Gene therapy medicinal products (GTMPs) have emerged as a transformative class of medicines. Defining what a certain class of medicines encompasses, and what it does not, is key, with ample...
2.
Prior S, Metcalfe C, Hufton S, Wadhwa M, Schneider C, Burns C
Nat Biotechnol
. 2021 Mar;
39(3):276-280.
PMID: 33664522
No abstract available.
3.
Page M, Almond N, Rose N, Schneider C
Nat Biotechnol
. 2020 May;
38(6):673-674.
PMID: 32444851
No abstract available.
4.
Abou-El-Enein M, Cathomen T, Ivics Z, June C, Renner M, Schneider C, et al.
Cell Stem Cell
. 2017 Oct;
21(4):427-430.
PMID: 28985524
As genome editing rapidly progresses toward the realization of its clinical promise, assessing the suitability of current tools and processes used for its benefit-risk assessment is critical. Although current regulations...
5.
Zhao Y, Stepto H, Schneider C
Hum Gene Ther Methods
. 2017 Jul;
28(4):205-214.
PMID: 28747142
Gene therapy is a rapidly evolving field. So far, there have been >2,400 gene therapy products in clinical trials and four products on the market. A prerequisite for producing gene...
6.
Abou-El-Enein M, Schneider C
Nat Biotechnol
. 2016 Mar;
34(3):231-3.
PMID: 26963541
No abstract available.
7.
Luciani F, Galluzzo S, Gaggioli A, Kruse N, Venneugues P, Schneider C, et al.
MAbs
. 2015 Apr;
7(3):451-5.
PMID: 25853461
Quality by design (QbD) is an innovative approach to drug development that has started to be implemented into the regulatory framework, but currently mainly for chemical drugs. The recent marketing...
8.
Salmikangas P, Menezes-Ferreira M, Reischl I, Tsiftsoglou A, Kyselovic J, Borg J, et al.
Regen Med
. 2015 Jan;
10(1):65-78.
PMID: 25562353
During the past decade, a large number of cell-based medicinal products have been tested in clinical trials for the treatment of various diseases and tissue defects. However, licensed products and...
9.
van Aerts L, De Smet K, Reichmann G, van der Laan J, Schneider C
MAbs
. 2014 Dec;
6(5):1155-62.
PMID: 25517301
The concept of biosimilars has spread from Europe to other regions throughout the world, and many regions have drafted regulatory guidelines for their development. Recently, a paradigm shift in regulatory...
10.
Weise M, Kurki P, Wolff-Holz E, Bielsky M, Schneider C
Blood
. 2014 Oct;
124(22):3191-6.
PMID: 25298038
Despite the establishment of a specific approval pathway, the issuance of detailed scientific guidelines for the development of similar biological medicinal products (so-called "biosimilars") and the approval of several biosimilars...